Danaher Corporation
New York Stock ExchangeCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Rainer Blair
- Full Time Employees
- 61,000
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2200 Pennsylvania Avenue, NW Washington DC United States of America 20037-1701
- IPO Date
- Dec 29, 1978
- CIK
- 0000313616
- Website
- danaher.com
- Similar Companies
- Business
- Danaher Corporation (NYSE: DHR), founded in 1984 and headquartered in Washington, D.C., operates as a leading global science and technology innovator focused on life sciences and diagnostics. The company conducts business through three primary segments: biotechnology, which develops products and services for therapeutic development including bioprocessing solutions, plasmid DNA, mRNA, proteins, and genomic medicines via brands such as Cytiva, Aldevron, and Abcam; life sciences, offering instruments like mass spectrometers, flow cytometry systems, microscopes, genomics consumables, lab automation, centrifugation, particle characterization, and gene and cell therapy tools; and diagnostics, providing clinical instruments, reagents, consumables, software, and services for disease diagnosis in hospitals, physicians' offices, reference laboratories, and critical care settings through subsidiaries including Cepheid and Beckman Coulter. Danaher serves customers worldwide across biopharmaceutical, research, healthcare, and precision medicine markets, employing approximately 63,000 associates in over 125 countries. Recent developments include the 2023 acquisition of Abcam for proteomic research consumables to accelerate drug discovery; a January 2025 investment partnership with Innovaccer Inc. through Danaher Diagnostics LLC and Danaher Ventures LLC to advance AI-enabled diagnostics and precision medicine; and a May 2025 diagnostic development and commercialization alliance with AstraZeneca to scale next-generation AI-powered diagnostics solutions.
Allspring Global Investments Holdings LLC Decreases Stake in Danaher Corporation $DHR
Will Danaher (DHR) Beat Estimates Again in Its Next Earnings Report?
Danaher Gears Up to Post Q2 Earnings: Is a Beat in the Offing?
Countdown to Danaher (DHR) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
Implied Volatility Surging for Danaher Stock Options
Danaher (DHR) Reports Next Week: Wall Street Expects Earnings Growth
Abbott Labs Vs. Danaher: Abbott's Everyday Products Beat Danaher's Slumping Biotech Equipment
VTRS or DHR: Which Is the Better Value Stock Right Now?
Will Strength in Biotechnology Unit Continue to Drive DHR's Growth?
Bet On These 5 Top-Ranked Stocks With Increasing P/E Ratios
Did Danaher Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Danaher Foundation Commits $1 Million to Ebola Outbreak Relief Efforts in Central Africa
The Big 3: JPM, DHR, MRK
Danaher (DHR) Crossed Above the 20-Day Moving Average: What That Means for Investors
Danaher Is Down 22% This Year. Is the Masimo Acquisition the Entry Point Investors Have Been Waiting for?
VTRS vs. DHR: Which Stock Is the Better Value Option?
Danaher Schedules Second Quarter 2026 Earnings Conference Call
The Best Stocks to Invest $1,000 in Right Now
The Healthcare M&A Wave
Danaher Boosts Product Portfolio With the Acquisition of Masimo